It is believed that if a vaccine could elicit potent antibodies to a specific conserved site in the V1V2 region, then the vaccine could protect people from HIV infection. The V1V2 is a region on the virus envelope which increases the susceptability to neutralistion by
"The new findings point the way toward a potentially more effective vaccine that would generate V1V2-directed HIV neutralising antibodies," said scientists from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health.
Scientists from Columbia University, the Centre for AIDS Programme of Research in South Africa, and the National Institute for Communicable Diseases, Johannesburg, were part of the research.
The team began its work by identifying an HIV-infected volunteer, who naturally developed V1V2-directed HIV neutralising antibodies after several months of infection.
"The new findings point the way toward a potentially more effective vaccine that would generate V1V2-directed HIV neutralising antibodies," said scientists from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health.
Scientists from Columbia University, the Centre for AIDS Programme of Research in South Africa, and the National Institute for Communicable Diseases, Johannesburg, were part of the research.
The team began its work by identifying an HIV-infected volunteer, who naturally developed V1V2-directed HIV neutralising antibodies after several months of infection.